{"id": "article-24011_0", "title": "Lambert-Eaton Myasthenic Syndrome -- Continuing Education Activity", "content": "Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular junction disorder affecting communication between nerves and muscles. This intricate disorder can manifest due to a paraneoplastic syndrome or a primary autoimmune disorder. The majority of cases are associated with small-cell lung cancer. This activity primarily focuses on analyzing the prominent clinical symptom of muscle weakness, which is driven by the development of antibodies that target voltage-gated calcium channels on presynaptic nerve terminals. As a result, the release of the acetylcholine neurotransmitter is reduced. This activity helps gain valuable insights into the intricate pathogenesis, practical diagnostic approaches, and tailored treatment strategies for LEMS. This activity also highlights the crucial role of the interprofessional healthcare team in coordinating the comprehensive management of this intricate syndrome.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Continuing Education Activity. Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular junction disorder affecting communication between nerves and muscles. This intricate disorder can manifest due to a paraneoplastic syndrome or a primary autoimmune disorder. The majority of cases are associated with small-cell lung cancer. This activity primarily focuses on analyzing the prominent clinical symptom of muscle weakness, which is driven by the development of antibodies that target voltage-gated calcium channels on presynaptic nerve terminals. As a result, the release of the acetylcholine neurotransmitter is reduced. This activity helps gain valuable insights into the intricate pathogenesis, practical diagnostic approaches, and tailored treatment strategies for LEMS. This activity also highlights the crucial role of the interprofessional healthcare team in coordinating the comprehensive management of this intricate syndrome."}
{"id": "article-24011_1", "title": "Lambert-Eaton Myasthenic Syndrome -- Continuing Education Activity", "content": "Objectives: Identify early clinical indicators of Lambert-Eaton myasthenic syndrome, such as proximal muscle weakness and autonomic dysfunction. Implement individualized symptomatic management strategies tailored to LEMS severity to optimize acetylcholine levels and neuromuscular transmission. Select the most suitable treatment options for LEMS patients based on the severity of weakness and malignancy association. Communicate effectively with LEMS patients and their families, explaining the diagnosis, treatment options, prognosis, and potential adverse effects and outcomes of the treatment. Access free multiple choice questions on this topic.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Continuing Education Activity. Objectives: Identify early clinical indicators of Lambert-Eaton myasthenic syndrome, such as proximal muscle weakness and autonomic dysfunction. Implement individualized symptomatic management strategies tailored to LEMS severity to optimize acetylcholine levels and neuromuscular transmission. Select the most suitable treatment options for LEMS patients based on the severity of weakness and malignancy association. Communicate effectively with LEMS patients and their families, explaining the diagnosis, treatment options, prognosis, and potential adverse effects and outcomes of the treatment. Access free multiple choice questions on this topic."}
{"id": "article-24011_2", "title": "Lambert-Eaton Myasthenic Syndrome -- Introduction", "content": "Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular junction disorder that may present as a\u00a0paraneoplastic syndrome or a primary autoimmune disorder.\u00a0The majority of cases are associated with\u00a0small-cell lung cancer (SCLC). [1] The primary clinical symptom is muscle weakness. The underlying pathophysiology involves the development of antibodies that target voltage-gated calcium channels (VGCCs) on presynaptic nerve terminals, resulting in reduced acetylcholine (ACh) neurotransmitter release. This activity reviews the pathogenesis, diagnostic procedures, and treatment strategies\u00a0for LEMS. [2] [3] [4] [5] [6]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Introduction. Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular junction disorder that may present as a\u00a0paraneoplastic syndrome or a primary autoimmune disorder.\u00a0The majority of cases are associated with\u00a0small-cell lung cancer (SCLC). [1] The primary clinical symptom is muscle weakness. The underlying pathophysiology involves the development of antibodies that target voltage-gated calcium channels (VGCCs) on presynaptic nerve terminals, resulting in reduced acetylcholine (ACh) neurotransmitter release. This activity reviews the pathogenesis, diagnostic procedures, and treatment strategies\u00a0for LEMS. [2] [3] [4] [5] [6]"}
{"id": "article-24011_3", "title": "Lambert-Eaton Myasthenic Syndrome -- Etiology", "content": "LEMS is categorized as either paraneoplastic or non-paraneoplastic, the latter being referred to as non-tumor LEMS (NT-LEMS). NT-LEMS\u00a0is characterized by its absence of association with malignancies.\u00a0Approximately 60% of LEMS patients have an underlying tumor, with the paraneoplastic form predominantly associated with SCLC. [1]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Etiology. LEMS is categorized as either paraneoplastic or non-paraneoplastic, the latter being referred to as non-tumor LEMS (NT-LEMS). NT-LEMS\u00a0is characterized by its absence of association with malignancies.\u00a0Approximately 60% of LEMS patients have an underlying tumor, with the paraneoplastic form predominantly associated with SCLC. [1]"}
{"id": "article-24011_4", "title": "Lambert-Eaton Myasthenic Syndrome -- Etiology", "content": "LEMS is also associated with\u00a0other malignancies, such as non-SCLC, mixed lung carcinoma, prostate cancer, thymoma, and lymphoproliferative disorders. Research has shown that the diagnosis of LEMS can precede the diagnosis of SCLC by 5 to 6 years. Furthermore, a significant risk factor for LEMS is having a history of smoking. The genetic association with HLA\u2013B8\u2013DR3 haplotype is present in about 65% of young patients with NT\u2013LEMS. [7]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Etiology. LEMS is also associated with\u00a0other malignancies, such as non-SCLC, mixed lung carcinoma, prostate cancer, thymoma, and lymphoproliferative disorders. Research has shown that the diagnosis of LEMS can precede the diagnosis of SCLC by 5 to 6 years. Furthermore, a significant risk factor for LEMS is having a history of smoking. The genetic association with HLA\u2013B8\u2013DR3 haplotype is present in about 65% of young patients with NT\u2013LEMS. [7]"}
{"id": "article-24011_5", "title": "Lambert-Eaton Myasthenic Syndrome -- Epidemiology", "content": "LEMS is a rare neuromuscular disorder with a prevalence 46 times lower than myasthenia gravis (MG). However, the annual incidence of LEMS is only 10 to 14 times less than that of MG. This contrast in prevalence underscores the challenging prognosis and survival rates of LEMS, particularly when associated with SCLC.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Epidemiology. LEMS is a rare neuromuscular disorder with a prevalence 46 times lower than myasthenia gravis (MG). However, the annual incidence of LEMS is only 10 to 14 times less than that of MG. This contrast in prevalence underscores the challenging prognosis and survival rates of LEMS, particularly when associated with SCLC."}
{"id": "article-24011_6", "title": "Lambert-Eaton Myasthenic Syndrome -- Epidemiology", "content": "Approximately 60% to 75% of LEMS patients are male, whereas MG has a female predilection.\u00a0The mean age at presentation for paraneoplastic LEMS in individuals is around age 58.\u00a0On the other hand, in cases of LEMS not\u00a0associated with an underlying malignancy, the age and gender distribution resemble that of MG. The onset age peaks at 35, with a larger peak at 60. LEMS not associated with malignancy exhibits a near-normal survival rate, providing a more favorable prognosis. [8] [9] [10]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Epidemiology. Approximately 60% to 75% of LEMS patients are male, whereas MG has a female predilection.\u00a0The mean age at presentation for paraneoplastic LEMS in individuals is around age 58.\u00a0On the other hand, in cases of LEMS not\u00a0associated with an underlying malignancy, the age and gender distribution resemble that of MG. The onset age peaks at 35, with a larger peak at 60. LEMS not associated with malignancy exhibits a near-normal survival rate, providing a more favorable prognosis. [8] [9] [10]"}
{"id": "article-24011_7", "title": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology", "content": "LEMS\u00a0is\u00a0characterized by a reduction in Ach release\u00a0from presynaptic nerve terminals, which arises from antibodies\u00a0targeting VGCCs within the presynaptic neuronal cell membrane. The standard process of ACh release and interaction in the neuromuscular junction are listed below.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology. LEMS\u00a0is\u00a0characterized by a reduction in Ach release\u00a0from presynaptic nerve terminals, which arises from antibodies\u00a0targeting VGCCs within the presynaptic neuronal cell membrane. The standard process of ACh release and interaction in the neuromuscular junction are listed below."}
{"id": "article-24011_8", "title": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology", "content": "ACh is synthesized and stored within synaptic vesicles at the motor nerve terminal. As an action potential\u00a0propagates\u00a0down the motor axon, it triggers the opening of\u00a0VGCCs on the presynaptic nerve terminal, leading to the influx of calcium ions into the terminal. This calcium influx through VGCCs then triggers the quantal release of ACh into the neuromuscular junction. ACh molecules bind to ACh receptors located on the postsynaptic neuron, causing a rapid influx of cations that leads to depolarization at the muscle fiber's end plate. This depolarization, in turn, initiates an action potential, ultimately triggering muscle contraction. The enzyme acetylcholinesterase rapidly hydrolyzes the ACh molecules present in the synaptic cleft.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology. ACh is synthesized and stored within synaptic vesicles at the motor nerve terminal. As an action potential\u00a0propagates\u00a0down the motor axon, it triggers the opening of\u00a0VGCCs on the presynaptic nerve terminal, leading to the influx of calcium ions into the terminal. This calcium influx through VGCCs then triggers the quantal release of ACh into the neuromuscular junction. ACh molecules bind to ACh receptors located on the postsynaptic neuron, causing a rapid influx of cations that leads to depolarization at the muscle fiber's end plate. This depolarization, in turn, initiates an action potential, ultimately triggering muscle contraction. The enzyme acetylcholinesterase rapidly hydrolyzes the ACh molecules present in the synaptic cleft."}
{"id": "article-24011_9", "title": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology", "content": "VGCC is a large transmembrane protein facilitating calcium ion influx into nerve terminals via multiple subunits. In LEMS, the functionality of VGCC is\u00a0compromised\u00a0due to the cross-linking of these channels mediated by IgG antibodies. More specifically, these antibodies specifically target the P/Q subtype of VGCC. Notably, 85% of patients with LEMS exhibit\u00a0antibodies against the P/Q-type VGCC. In malignancy-associated LEMS, antibodies against the N-type VGCC have been sporadically identified.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology. VGCC is a large transmembrane protein facilitating calcium ion influx into nerve terminals via multiple subunits. In LEMS, the functionality of VGCC is\u00a0compromised\u00a0due to the cross-linking of these channels mediated by IgG antibodies. More specifically, these antibodies specifically target the P/Q subtype of VGCC. Notably, 85% of patients with LEMS exhibit\u00a0antibodies against the P/Q-type VGCC. In malignancy-associated LEMS, antibodies against the N-type VGCC have been sporadically identified."}
{"id": "article-24011_10", "title": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology", "content": "Autoimmunity within the context of LEMS associated with SCLC follows a distinct mechanism. In these instances, the tumor tissue expresses VGCC. This\u00a0antigenic expression\u00a0within the tumor cells\u00a0triggers\u00a0autoantibody production. These autoantibodies exhibit cross-reactivity with presynaptic VGCC antigens.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology. Autoimmunity within the context of LEMS associated with SCLC follows a distinct mechanism. In these instances, the tumor tissue expresses VGCC. This\u00a0antigenic expression\u00a0within the tumor cells\u00a0triggers\u00a0autoantibody production. These autoantibodies exhibit cross-reactivity with presynaptic VGCC antigens."}
{"id": "article-24011_11", "title": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology", "content": "Non-tumor LEMS has a genetic predisposition associated with\u00a0specific HLA alleles, including HLA-B8 (HLA class I), HLA-DR3, and HLA-DQ2 (HLA class II). These HLA alleles have also been identified in individuals with other autoimmune conditions, including MG. However, it is noteworthy that this genetic association is not observed in LEMS cases linked to SCLC.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology. Non-tumor LEMS has a genetic predisposition associated with\u00a0specific HLA alleles, including HLA-B8 (HLA class I), HLA-DR3, and HLA-DQ2 (HLA class II). These HLA alleles have also been identified in individuals with other autoimmune conditions, including MG. However, it is noteworthy that this genetic association is not observed in LEMS cases linked to SCLC."}
{"id": "article-24011_12", "title": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology", "content": "LEMS is a B-cell\u2013mediated autoimmune neurological disorder specifically targeting the cell surface antigen (VGCC). The VGCC-IgG antibody is central to this disorder and directly contributes to its\u00a0pathogenesis, leading to compromised\u00a0neuromuscular transmission and manifesting as observable muscle weakness. Profoundly diminished deep tendon reflexes serve as a distinctive hallmark.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology. LEMS is a B-cell\u2013mediated autoimmune neurological disorder specifically targeting the cell surface antigen (VGCC). The VGCC-IgG antibody is central to this disorder and directly contributes to its\u00a0pathogenesis, leading to compromised\u00a0neuromuscular transmission and manifesting as observable muscle weakness. Profoundly diminished deep tendon reflexes serve as a distinctive hallmark."}
{"id": "article-24011_13", "title": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology", "content": "In addition to muscle-related symptoms, the effects extend to the release of ACh\u2014a neurotransmitter also relevant to autonomic ganglia. Consequently, this disruption results in clinical manifestations of autonomic involvement, including constipation and atypical pupillary responses to light stimuli.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Pathophysiology. In addition to muscle-related symptoms, the effects extend to the release of ACh\u2014a neurotransmitter also relevant to autonomic ganglia. Consequently, this disruption results in clinical manifestations of autonomic involvement, including constipation and atypical pupillary responses to light stimuli."}
{"id": "article-24011_14", "title": "Lambert-Eaton Myasthenic Syndrome -- History and Physical", "content": "The predominant clinical features of LEMS include proximal muscle weakness, autonomic dysfunction, and impaired deep tendon reflexes. The\u00a0symptoms of LEMS typically have an insidious onset and progress more rapidly in cases of SCLC-LEMS. Muscle weakness predominantly involves the proximal lower extremities, leading to difficulties transitioning from a seated posture. The pattern of muscle involvement is usually symmetrical and characterized by\u00a0progression from proximal to distal and caudal to cranial regions,\u00a0eventually reaching the oculobulbar area. Patients\u00a0often\u00a0report\u00a0sensations of dull aching or stiffness. Upon clinical assessment, significant hyporeflexia or areflexia is\u00a0evident with limited muscle atrophy. A characteristic feature of LEMS is post-exercise or post-activation facilitation, characterized by enhanced deep tendon reflexes and muscle strength after repeated muscle contractions. This effect becomes particularly pronounced when evaluated after a brief rest period.", "contents": "Lambert-Eaton Myasthenic Syndrome -- History and Physical. The predominant clinical features of LEMS include proximal muscle weakness, autonomic dysfunction, and impaired deep tendon reflexes. The\u00a0symptoms of LEMS typically have an insidious onset and progress more rapidly in cases of SCLC-LEMS. Muscle weakness predominantly involves the proximal lower extremities, leading to difficulties transitioning from a seated posture. The pattern of muscle involvement is usually symmetrical and characterized by\u00a0progression from proximal to distal and caudal to cranial regions,\u00a0eventually reaching the oculobulbar area. Patients\u00a0often\u00a0report\u00a0sensations of dull aching or stiffness. Upon clinical assessment, significant hyporeflexia or areflexia is\u00a0evident with limited muscle atrophy. A characteristic feature of LEMS is post-exercise or post-activation facilitation, characterized by enhanced deep tendon reflexes and muscle strength after repeated muscle contractions. This effect becomes particularly pronounced when evaluated after a brief rest period."}
{"id": "article-24011_15", "title": "Lambert-Eaton Myasthenic Syndrome -- History and Physical", "content": "Oculobulbar weakness is a prominent feature of LEMS, with cranial nerve involvement observed in approximately 70% of patients. The most common cranial nerve manifestations include ocular symptoms such as ptosis and diplopia. Furthermore, dysphagia and dysarthria may manifest, typically appearing in the advanced stages of the disease. Autonomic dysfunction is\u00a0a prevailing concern in LEMS, affecting a significant proportion of patients, with a prevalence ranging from 80% to 96%. The most frequently reported symptom is a dry mouth. Other associated symptoms include erectile dysfunction in men, constipation, orthostatic dysfunction, and altered perspiration. Respiratory failure\u00a0is a relatively rare\u00a0occurrence in the\u00a0advanced stages of LEMS.", "contents": "Lambert-Eaton Myasthenic Syndrome -- History and Physical. Oculobulbar weakness is a prominent feature of LEMS, with cranial nerve involvement observed in approximately 70% of patients. The most common cranial nerve manifestations include ocular symptoms such as ptosis and diplopia. Furthermore, dysphagia and dysarthria may manifest, typically appearing in the advanced stages of the disease. Autonomic dysfunction is\u00a0a prevailing concern in LEMS, affecting a significant proportion of patients, with a prevalence ranging from 80% to 96%. The most frequently reported symptom is a dry mouth. Other associated symptoms include erectile dysfunction in men, constipation, orthostatic dysfunction, and altered perspiration. Respiratory failure\u00a0is a relatively rare\u00a0occurrence in the\u00a0advanced stages of LEMS."}
{"id": "article-24011_16", "title": "Lambert-Eaton Myasthenic Syndrome -- Evaluation", "content": "Clinical features such as proximal muscle weakness associated with areflexia and autonomic dysfunction should raise suspicion and prompt an evaluation for LEMS. This diagnosis\u00a0can be confirmed through P/Q-type VGCC and electrodiagnostic studies (EDS).", "contents": "Lambert-Eaton Myasthenic Syndrome -- Evaluation. Clinical features such as proximal muscle weakness associated with areflexia and autonomic dysfunction should raise suspicion and prompt an evaluation for LEMS. This diagnosis\u00a0can be confirmed through P/Q-type VGCC and electrodiagnostic studies (EDS)."}
{"id": "article-24011_17", "title": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Serology", "content": "Antibodies directed against P/Q-type VGCC, as detected in a radioimmunoassay, are present in approximately 85% to 95% of\u00a0individuals with LEMS. However, it is noteworthy that P/Q-type VGCCs are not exclusive to LEMS, as they have also been linked to various other neurological conditions and autoimmune disorders.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Serology. Antibodies directed against P/Q-type VGCC, as detected in a radioimmunoassay, are present in approximately 85% to 95% of\u00a0individuals with LEMS. However, it is noteworthy that P/Q-type VGCCs are not exclusive to LEMS, as they have also been linked to various other neurological conditions and autoimmune disorders."}
{"id": "article-24011_18", "title": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Serology", "content": "In LEMS, antibodies targeting N-type VGCC are observed less frequently, accounting for only 30% to 40% of cases. In addition, 64% of patients with LEMS\u00a0and SCLC also were found to have antibodies against SOX1\u2014an immunogenic tumor antigen in SCLC with a 95% specificity. [11]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Serology. In LEMS, antibodies targeting N-type VGCC are observed less frequently, accounting for only 30% to 40% of cases. In addition, 64% of patients with LEMS\u00a0and SCLC also were found to have antibodies against SOX1\u2014an immunogenic tumor antigen in SCLC with a 95% specificity. [11]"}
{"id": "article-24011_19", "title": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Electrodiagnostic Testing", "content": "When clinical suspicion arises regarding LEMS, EDS provides valuable assistance in confirming the diagnosis. EDS typically begins with nerve conduction studies (NCS) and electromyography (EMG). Sensory studies conducted as part of NCS typically show normal results, with unaffected nerve conduction velocities. In contrast, motor unit amplitudes are generally significantly reduced.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Electrodiagnostic Testing. When clinical suspicion arises regarding LEMS, EDS provides valuable assistance in confirming the diagnosis. EDS typically begins with nerve conduction studies (NCS) and electromyography (EMG). Sensory studies conducted as part of NCS typically show normal results, with unaffected nerve conduction velocities. In contrast, motor unit amplitudes are generally significantly reduced."}
{"id": "article-24011_20", "title": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Electrodiagnostic Testing", "content": "Repetitive nerve stimulation (RNS) is an essential component of EDS, which commonly reveals a decremental response during low-frequency repetitive nerve stimulation and an incremental response at high-rate stimulation. Although these findings are generally consistent and reproducible, varying results have also been reported.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Electrodiagnostic Testing. Repetitive nerve stimulation (RNS) is an essential component of EDS, which commonly reveals a decremental response during low-frequency repetitive nerve stimulation and an incremental response at high-rate stimulation. Although these findings are generally consistent and reproducible, varying results have also been reported."}
{"id": "article-24011_21", "title": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Electrodiagnostic Testing", "content": "Following high-frequency RNS or post-exercise testing, a significant incremental response becomes evident, often exceeding 100% in compound muscle action potential (CMAP) amplitude. Notably, a diagnostic threshold is typically reached with an increase ranging from 60% to 99%. Furthermore, needle EMG can reveal the presence of unstable action potentials.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Electrodiagnostic Testing. Following high-frequency RNS or post-exercise testing, a significant incremental response becomes evident, often exceeding 100% in compound muscle action potential (CMAP) amplitude. Notably, a diagnostic threshold is typically reached with an increase ranging from 60% to 99%. Furthermore, needle EMG can reveal the presence of unstable action potentials."}
{"id": "article-24011_22", "title": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Electrodiagnostic Testing", "content": "Single-fiber EMG (SFEMG) is the most sensitive test for neuromuscular junction disorders. In LEMS,\u00a0this test often shows a significant increase in jitter and transmission block (jitter block), which is characteristically improved at higher firing rates. Although SFEMG is more sensitive than RNS, RNS remains widely available and notably valuable. RNS aids in\u00a0differentiating between MG and LEMS, accomplishing this differentiation by highlighting post-exercise facilitation in LEMS as opposed to decrement in MG.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Electrodiagnostic Testing. Single-fiber EMG (SFEMG) is the most sensitive test for neuromuscular junction disorders. In LEMS,\u00a0this test often shows a significant increase in jitter and transmission block (jitter block), which is characteristically improved at higher firing rates. Although SFEMG is more sensitive than RNS, RNS remains widely available and notably valuable. RNS aids in\u00a0differentiating between MG and LEMS, accomplishing this differentiation by highlighting post-exercise facilitation in LEMS as opposed to decrement in MG."}
{"id": "article-24011_23", "title": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Screening for Malignancy", "content": "Due to the\u00a0strong\u00a0association with malignancy,\u00a0a diagnosis of\u00a0LEMS\u00a0warrants\u00a0an immediate and extensive\u00a0investigation for an underlying malignancy. The initial recommended imaging study is a computed tomography (CT) or magnetic resonance imaging (MRI) chest scan. A positron emission tomography (PET) scan is also used for initial screening if CT is negative. If the initial evaluation does not reveal any malignancy, it is recommended to continue cancer screening every 3 to 6 months for a minimum of 2 years.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Screening for Malignancy. Due to the\u00a0strong\u00a0association with malignancy,\u00a0a diagnosis of\u00a0LEMS\u00a0warrants\u00a0an immediate and extensive\u00a0investigation for an underlying malignancy. The initial recommended imaging study is a computed tomography (CT) or magnetic resonance imaging (MRI) chest scan. A positron emission tomography (PET) scan is also used for initial screening if CT is negative. If the initial evaluation does not reveal any malignancy, it is recommended to continue cancer screening every 3 to 6 months for a minimum of 2 years."}
{"id": "article-24011_24", "title": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Screening for Malignancy", "content": "Individuals at higher risk, particularly those with a Dutch-English LEMS Tumor Association Prediction (DELTA-P) score exceeding 2 or positive SOX antibodies associated with SCLC-LEMS, should undergo screening every 3 months as recommended. The DELTA-P score consists of variables such as the age\u00a0at diagnosis and smoking history to assist in stratifying the risk of SCLC in LEMS patients. This score helps determine the frequency and depth of screening for underlying malignancies. [12]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Evaluation -- Screening for Malignancy. Individuals at higher risk, particularly those with a Dutch-English LEMS Tumor Association Prediction (DELTA-P) score exceeding 2 or positive SOX antibodies associated with SCLC-LEMS, should undergo screening every 3 months as recommended. The DELTA-P score consists of variables such as the age\u00a0at diagnosis and smoking history to assist in stratifying the risk of SCLC in LEMS patients. This score helps determine the frequency and depth of screening for underlying malignancies. [12]"}
{"id": "article-24011_25", "title": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management", "content": "In cases of LEMS associated with SCLC, it is essential to address the root cause by treating the underlying malignancy. [2] [13] [14] In addition to treating the underlying cancer, managing symptoms is the key approach for LEMS treatment, which includes various options. However, the most effective and theoretically sound interventions focus on improving presynaptic ACh release; some are mentioned below.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management. In cases of LEMS associated with SCLC, it is essential to address the root cause by treating the underlying malignancy. [2] [13] [14] In addition to treating the underlying cancer, managing symptoms is the key approach for LEMS treatment, which includes various options. However, the most effective and theoretically sound interventions focus on improving presynaptic ACh release; some are mentioned below."}
{"id": "article-24011_26", "title": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management", "content": "Amifampridine or 3,4-diaminopyridine (3,4-DAP): This medication blocks presynaptic potassium channels, prolonging the\u00a0action potential duration. This elongation leads to\u00a0increased presynaptic calcium influx and subsequent ACh release. It is considered the first-line symptomatic treatment. The recommended dosage for adults is 15 to 30 mg, administered 3 times daily. [15]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management. Amifampridine or 3,4-diaminopyridine (3,4-DAP): This medication blocks presynaptic potassium channels, prolonging the\u00a0action potential duration. This elongation leads to\u00a0increased presynaptic calcium influx and subsequent ACh release. It is considered the first-line symptomatic treatment. The recommended dosage for adults is 15 to 30 mg, administered 3 times daily. [15]"}
{"id": "article-24011_27", "title": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management", "content": "Acetylcholinesterase inhibitors: Although pyridostigmine is an acetylcholinesterase inhibitor used to address weakness, its effects are generally less pronounced than in the case of patients with MG.\u00a0The recommended adult dosage for this drug\u00a0is 30 to 120 mg, administered every 3 to 6 hours.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management. Acetylcholinesterase inhibitors: Although pyridostigmine is an acetylcholinesterase inhibitor used to address weakness, its effects are generally less pronounced than in the case of patients with MG.\u00a0The recommended adult dosage for this drug\u00a0is 30 to 120 mg, administered every 3 to 6 hours."}
{"id": "article-24011_28", "title": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management", "content": "Guanidine: This compound enhances ACh release following a nerve action potential. Guanidine should be considered only when amifampridine is unavailable due to its significant adverse effects and potential renal toxicity. [16] The recommended adult dosage is 1 g daily.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management. Guanidine: This compound enhances ACh release following a nerve action potential. Guanidine should be considered only when amifampridine is unavailable due to its significant adverse effects and potential renal toxicity. [16] The recommended adult dosage is 1 g daily."}
{"id": "article-24011_29", "title": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management", "content": "In cases where patients continue to have an enduring weakness that does not respond to symptomatic treatments, it becomes necessary to consider immunomodulating or immunosuppressive therapies, some of which are mentioned below.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management. In cases where patients continue to have an enduring weakness that does not respond to symptomatic treatments, it becomes necessary to consider immunomodulating or immunosuppressive therapies, some of which are mentioned below."}
{"id": "article-24011_30", "title": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management", "content": "Intravenous immune globulin (IVIG): IVIG is the primary treatment option for refractory cases. Despite its uncertain mechanism of action, it is believed to function by neutralizing autoantibodies and regulating autoreactive B cells. The usual regimen involves administering 2 g/kg over 2 to 5 days. [16]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management. Intravenous immune globulin (IVIG): IVIG is the primary treatment option for refractory cases. Despite its uncertain mechanism of action, it is believed to function by neutralizing autoantibodies and regulating autoreactive B cells. The usual regimen involves administering 2 g/kg over 2 to 5 days. [16]"}
{"id": "article-24011_31", "title": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management", "content": "Steroids and other immunosuppressive agents: Although azathioprine, mycophenolate, and cyclosporine may be considered for specific cases, their efficacy is generally lower\u00a0than IVIG. In addition, the potential for significant adverse effects often limits their widespread use.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management. Steroids and other immunosuppressive agents: Although azathioprine, mycophenolate, and cyclosporine may be considered for specific cases, their efficacy is generally lower\u00a0than IVIG. In addition, the potential for significant adverse effects often limits their widespread use."}
{"id": "article-24011_32", "title": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management", "content": "Rituximab: This monoclonal antibody\u00a0targets CD20 receptors found on B lymphocytes. Theoretically, it is effective against all B-cell-mediated diseases, including LEMS. Nevertheless, data supporting its more extensive utilization is insufficient. [16] Plasma exchange: In certain refractory cases, plasma exchange holds the potential to offer benefits.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Treatment / Management. Rituximab: This monoclonal antibody\u00a0targets CD20 receptors found on B lymphocytes. Theoretically, it is effective against all B-cell-mediated diseases, including LEMS. Nevertheless, data supporting its more extensive utilization is insufficient. [16] Plasma exchange: In certain refractory cases, plasma exchange holds the potential to offer benefits."}
{"id": "article-24011_33", "title": "Lambert-Eaton Myasthenic Syndrome -- Differential Diagnosis", "content": "The differential diagnosis of\u00a0LEMS includes MG. The distinguishing features include areflexia, autonomic dysfunction, and the post-exercise facilitation phenomenon specific to LEMS. Myopathies are also substantial considerations in the diagnostic process. The absence of sensory symptoms assists in excluding polyneuropathy or polyradiculopathies.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Differential Diagnosis. The differential diagnosis of\u00a0LEMS includes MG. The distinguishing features include areflexia, autonomic dysfunction, and the post-exercise facilitation phenomenon specific to LEMS. Myopathies are also substantial considerations in the diagnostic process. The absence of sensory symptoms assists in excluding polyneuropathy or polyradiculopathies."}
{"id": "article-24011_34", "title": "Lambert-Eaton Myasthenic Syndrome -- Prognosis", "content": "Patients diagnosed with LEMS often experience a\u00a0diminished quality of life\u00a0due to weakness, autonomic involvement, and potential treatment-related adverse effects. However, LEMS typically responds positively to symptomatic and immunosuppressive therapies.\u00a0Upon diagnosis,\u00a0approximately 60% of patients maintain their independence in daily activities, and this proportion increases to 85% within a year of treatment. [17]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Prognosis. Patients diagnosed with LEMS often experience a\u00a0diminished quality of life\u00a0due to weakness, autonomic involvement, and potential treatment-related adverse effects. However, LEMS typically responds positively to symptomatic and immunosuppressive therapies.\u00a0Upon diagnosis,\u00a0approximately 60% of patients maintain their independence in daily activities, and this proportion increases to 85% within a year of treatment. [17]"}
{"id": "article-24011_35", "title": "Lambert-Eaton Myasthenic Syndrome -- Prognosis", "content": "The life expectancy of LEMS patients depends on whether it is paraneoplastic or non-paraneoplastic (NT-LEMS). Survival for NT-LEMS patients is similar to the general population. Conversely, the prognosis for paraneoplastic LEMS patients depends\u00a0upon the underlying cancer. Most commonly, SCLC is the associated malignancy.\u00a0Intriguingly,\u00a0individuals with LEMS-SCLC\u00a0exhibit\u00a0more favorable survival rates than those with\u00a0non-LEMS SCLC, with an overall median survival of 17 months compared to 7 months ( P < .0001). [17]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Prognosis. The life expectancy of LEMS patients depends on whether it is paraneoplastic or non-paraneoplastic (NT-LEMS). Survival for NT-LEMS patients is similar to the general population. Conversely, the prognosis for paraneoplastic LEMS patients depends\u00a0upon the underlying cancer. Most commonly, SCLC is the associated malignancy.\u00a0Intriguingly,\u00a0individuals with LEMS-SCLC\u00a0exhibit\u00a0more favorable survival rates than those with\u00a0non-LEMS SCLC, with an overall median survival of 17 months compared to 7 months ( P < .0001). [17]"}
{"id": "article-24011_36", "title": "Lambert-Eaton Myasthenic Syndrome -- Complications", "content": "Complications associated with LEMS can be categorized into those originating from the condition and resulting from treatment. Issues stemming from LEMS include weakness-related complications such as falls, fractures, and aspiration pneumonia. Autonomic involvement\u00a0contributes to complications such as\u00a0dry mouth, constipation, dysphagia, and erectile dysfunction, resulting in weight loss and emaciation.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Complications. Complications associated with LEMS can be categorized into those originating from the condition and resulting from treatment. Issues stemming from LEMS include weakness-related complications such as falls, fractures, and aspiration pneumonia. Autonomic involvement\u00a0contributes to complications such as\u00a0dry mouth, constipation, dysphagia, and erectile dysfunction, resulting in weight loss and emaciation."}
{"id": "article-24011_37", "title": "Lambert-Eaton Myasthenic Syndrome -- Complications", "content": "On the other hand, treatment-related complications encompass adverse effects of medications. Symptoms such as tingling and numbness associated with 3,4-DAP can occur. Furthermore, complications such as cytopenia and infections might develop due to immunosuppressive drugs.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Complications. On the other hand, treatment-related complications encompass adverse effects of medications. Symptoms such as tingling and numbness associated with 3,4-DAP can occur. Furthermore, complications such as cytopenia and infections might develop due to immunosuppressive drugs."}
{"id": "article-24011_38", "title": "Lambert-Eaton Myasthenic Syndrome -- Deterrence and Patient Education", "content": "LEMS typically presents with a gradual onset and a progressively advancing course. The excessive fatigue patients report is frequently disproportionate to the degree of observed muscle weakness during a physical examination. A high index of suspicion is crucial for clinicians to make a timely diagnosis. Clinicians must also remain vigilant concerning autonomic symptoms, with dry mouth being the most frequently reported issue, followed by male impotence and constipation.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Deterrence and Patient Education. LEMS typically presents with a gradual onset and a progressively advancing course. The excessive fatigue patients report is frequently disproportionate to the degree of observed muscle weakness during a physical examination. A high index of suspicion is crucial for clinicians to make a timely diagnosis. Clinicians must also remain vigilant concerning autonomic symptoms, with dry mouth being the most frequently reported issue, followed by male impotence and constipation."}
{"id": "article-24011_39", "title": "Lambert-Eaton Myasthenic Syndrome -- Deterrence and Patient Education", "content": "LEMS diagnosis often precedes the diagnosis of SCLC over several years. Prompt and accurate diagnosis, facilitated by electrophysiological testing and\u00a0VGCC antibody testing, will lead to a careful search for underlying malignancy. Patient education is crucial regarding their diagnosis, treatment options, prognosis, and potential treatment-related adverse effects. This empowerment enables patients and their families to understand the illness and what to expect moving forward comprehensively. [18]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Deterrence and Patient Education. LEMS diagnosis often precedes the diagnosis of SCLC over several years. Prompt and accurate diagnosis, facilitated by electrophysiological testing and\u00a0VGCC antibody testing, will lead to a careful search for underlying malignancy. Patient education is crucial regarding their diagnosis, treatment options, prognosis, and potential treatment-related adverse effects. This empowerment enables patients and their families to understand the illness and what to expect moving forward comprehensively. [18]"}
{"id": "article-24011_40", "title": "Lambert-Eaton Myasthenic Syndrome -- Enhancing Healthcare Team Outcomes", "content": "Due to the diverse clinical presentation of LEMS,\u00a0collaboration among interprofessional healthcare teams is crucial for diagnosing and managing the condition in patients. Given its frequent association with malignancy, the team should comprise an oncologist, surgeon, hematologist, ophthalmologist, neurologist, primary care provider, and nurse practitioner.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Enhancing Healthcare Team Outcomes. Due to the diverse clinical presentation of LEMS,\u00a0collaboration among interprofessional healthcare teams is crucial for diagnosing and managing the condition in patients. Given its frequent association with malignancy, the team should comprise an oncologist, surgeon, hematologist, ophthalmologist, neurologist, primary care provider, and nurse practitioner."}
{"id": "article-24011_41", "title": "Lambert-Eaton Myasthenic Syndrome -- Enhancing Healthcare Team Outcomes", "content": "The primary objective of initial treatment for LEMS, whether associated with malignancy or not, is to elevate ACh levels for\u00a0symptomatic management. In cases of refractory weakness, the recommended first-line\u00a0immunosuppressive approach involves IVIG. Other suggested alternatives include prednisone, rituximab, azathioprine, or plasma exchange.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Enhancing Healthcare Team Outcomes. The primary objective of initial treatment for LEMS, whether associated with malignancy or not, is to elevate ACh levels for\u00a0symptomatic management. In cases of refractory weakness, the recommended first-line\u00a0immunosuppressive approach involves IVIG. Other suggested alternatives include prednisone, rituximab, azathioprine, or plasma exchange."}
{"id": "article-24011_42", "title": "Lambert-Eaton Myasthenic Syndrome -- Enhancing Healthcare Team Outcomes", "content": "The prognosis for individuals with this syndrome is contingent on the primary malignancy. In cases of advanced disease, the prognosis tends to be bleak. However, if the primary malignancy is controlled, symptomatic improvement\u00a0gradually\u00a0occurs. However, symptomatic improvement typically occurs gradually with control of the primary malignancy. Nevertheless, it is noteworthy that complete recovery is often unattainable. [19] [20]", "contents": "Lambert-Eaton Myasthenic Syndrome -- Enhancing Healthcare Team Outcomes. The prognosis for individuals with this syndrome is contingent on the primary malignancy. In cases of advanced disease, the prognosis tends to be bleak. However, if the primary malignancy is controlled, symptomatic improvement\u00a0gradually\u00a0occurs. However, symptomatic improvement typically occurs gradually with control of the primary malignancy. Nevertheless, it is noteworthy that complete recovery is often unattainable. [19] [20]"}
{"id": "article-24011_43", "title": "Lambert-Eaton Myasthenic Syndrome -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Lambert-Eaton Myasthenic Syndrome -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}